

HeraMED Investor Update Webinar

HeraMED Limited (ASX: HMD) ('HeraMED' or the 'Company'), a medical data and technology company pioneering digital maternity care, is pleased to announce that it will host an investor update webinar, following recent announcements regarding its new partnerships with global health technology leader Royal Philips ("Philips") (NYSE:PHG), and pilot launch with major US health system Lee Health.

HeraMED Managing Director and Chief Executive Officer Anoushka Gungadin will discuss the Company's recent activities and outlook for 2026 before providing an opportunity for investors to ask questions. She will be joined by HeraMED Non-Executive Director Dr Sharon Howell, Advisory Board member/Acting CTO Vivek Krishnan and Chief Clinical Transformation Officer/CMO Dr Mandy Khaira.

WEBINAR DETAILS

Date: Thursday 4 December 2025

Time: 10:30am AEDT

Register for the webinar at the link below:

https://us02web.zoom.us/webinar/register/WN_84hAq1LiRmyZcOKOXcRnRA

Please submit any questions to: matt@nwrcommunications.com.au

After registering, you will receive a confirmation email containing information about joining the webinar.

ENDS

This announcement has been authorised by the Managing Director & CEO of HeraMED Limited.

HeraMED Limited

Managing Director & CEO

Anoushka Gungadin

M: +61 431 131 649

E: anoushka@hera-med.com

CFO & Company Secretary

Cameron Jones

T: +61 400 086 399

E: cameron.jones@bio101.com

Chairman

Tim Chapman

T: +61 419 897 062

E: tchapman@claritycap.com.au

Media / Investor Relations

Matthew Wright

M: +61 451 896 420

E: matt@nwrcommunications.com.au

About HeraMED Limited (ASX: HMD)

HeraMED is an innovative medical data and technology company leading the digital transformation of maternity care by revolutionising the prenatal and postpartum experience with its hybrid maternity care platform. HeraMED offers a proprietary platform that utilises hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence, and big data.

The Company's proprietary offering, HeraCARE, has been engineered to offer a fully integrated maternal health ecosystem designed to deliver better care at a lower cost, ensure expectant mothers are engaged, informed and well-supported, allow healthcare professionals to provide the highest quality care and enable early detection and prevention of potential risks.